Drugs for Hypophosphatemic Rickets, X-Linked Dominant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 43)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cholecalciferol |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
67-97-0, 1406-16-2 |
5280795 10883523 |
Synonyms:
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,4E,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3BETA,Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
(3Î’,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
3-BETA,Z,7E-9,10-SECOCHOLESTR-5,7,10(19)-TRIEN-3-OL
7-DEHYDROCHOLESTEROL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
ACCRETE D3
ACIFEROL D3
ACTIVATED
Activated 7-dehydrocholesterol
ADCAL-D3
ARACHITOL
AVITICOL
BIOLIFE VITAMIN D3
BIO-VITAMIN D3
CACIT D3
CALCEOS
CALCICHEW D3
CALCICHEW D3 FTE
CALCICHEW D3 ONCE DAILY
CALCI-D
Calciferol
Calciol
CALDRINK D3
CALFOVIT D3
CC
Cholecalciferol
CHOLECALCIFEROL D3
Cholecalciferols
Cholecalciferolum
COLECAL D3
Colecalciferol
Colecalciferolum
COLEKAL-D3
COLEVIT D3
CUBICOLE D3
D3 LEMON MELTS
D3-50
D3-VIGANTOL
DEKRISTOL
DELSTEROL
Delta-D
DEPARAL
DESUNIN
DEVARON
Dihydrocholesterol
DLUX 400
D-MAX
D-TRACETTEN
|
D-VIT3
EBIVIT
E-D3
EVACAL D3
FERACOL
FULTIUM DAILY D3
FULTIUM-D3
GRANUVIT D3
HUX D3
INVITA D3
ISO D3
KORA LIQUID
MICRO-DEE
NATECAL D3
NATURE'S REMEDY VITAMIN D3
NEO-D
NPHD3
NSC-375571
Oleovitamin D3
OSTEOCAPS D3
PLENACHOL
PRO D3
PRO D3 FOLIC
PRO D3 FORTE
PROVITINA
QUINTOX
RICKETON
ROYALVIT D3
STEXEROL-D3
STIVIT-D3
SUNVIT-D3 1,000
SUNVIT-D3 10,000
SUNVIT-D3 2,000
SUNVIT-D3 20,000
SUNVIT-D3 3,000
SUNVIT-D3 400
SUNVIT-D3 5,000
SUNVIT-D3 50,000
SUNVIT-D3 800
SYNERVIT-D3
THEICAL D-3
THORENS
TRIVITAN
VIDDE-3-HYDROSOL
VI-DE3
VIDEKHOL
VIGANTOL
VIGANTOLETTEN
VIGANTOLETTEN 500
VIGORSAN
VIT D3 STREULI
VITA-D3
VITAMIN D
Vitamin D 3
VITAMIN D ASSAY SYSTEM SUITABILITY
Vitamin D NOS
Vitamin D, unspecified form
Vitamin D3
Vitamin D-3
VITINC DAN-DEE-3
ZYMAD
δ-D
|
|
2 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
3 |
|
Antibodies, Monoclonal |
|
Phase 4 |
|
|
|
4 |
|
Vitamins |
|
Phase 4 |
|
|
|
5 |
|
Trace Elements |
|
Phase 4 |
|
|
|
6 |
|
Calciferol |
|
Phase 4 |
|
|
|
7 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
8 |
|
Micronutrients |
|
Phase 4 |
|
|
|
9 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
10 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
11 |
|
Antibodies |
|
Phase 4 |
|
|
|
12 |
|
Parathyroid hormone |
Approved, Investigational |
Phase 3 |
|
9002-64-6 |
|
Synonyms:
ALX1-11
ALX-111
ALX-1-11
NPSP558
NPSP-558
Parathormone
Parathormone (human recombinant)
Parathyrin
PARATHYROID HORMONE
Parathyroid hormone (1-84) human recombinant
|
Parathyroid hormone (rDNA)
PAROIDIN
PREOTACT
PTH
PTH(1-84)
rhPTH
rhPTH(1-84)
rPTH
rPTH(1-84)
|
|
13 |
|
Sodium fluoride |
Approved |
Phase 3 |
|
7681-49-4 |
|
Synonyms:
Fluoride, sodium
Fluorides, sodium
Fluorinse
Fluoristat
Fluoristats
NaF
Ossin
|
Ossins
Procter and gamble brand OF sodium fluoride
Sodium fluoride
Sodium fluorides
Zymafluor
Zymafluors
|
|
14 |
|
Mitogens |
|
Phase 3 |
|
|
|
15 |
|
Listerine |
|
Phase 3 |
|
|
|
16 |
|
Fluorides, Topical |
|
Phase 3 |
|
|
|
17 |
|
Fluorides |
|
Phase 3 |
|
|
|
18 |
|
Protective Agents |
|
Phase 3 |
|
|
|
19 |
|
Immunoglobulins, Intravenous |
|
Phase 1, Phase 2 |
|
|
|
20 |
|
Immunoglobulin Fc Fragments |
|
Phase 1, Phase 2 |
|
|
|
21 |
|
Sevelamer |
Approved |
|
|
52757-95-6 |
3085017 |
Synonyms:
RENAGEL
RENVELA
Sevelamer
|
Sévélamer
Sevelamero
Sevelamerum
|
|
22 |
|
Salmon calcitonin |
Approved, Investigational |
|
|
47931-85-1 |
155817456 |
Synonyms:
CALCITONIN (SALMON SYNTHETIC)
Calcitonin salmon
CALCITONIN SALMON RECOMBINANT
Calcitonin, salmon
Calcitonina salmón sintética
|
Calcitonin-salmon
CT (salmon)|Miacalcin®
FORTICAL
Recombinant salmon calcitonin
Salmon calcitonin
|
|
23 |
|
Sodium citrate |
Approved, Investigational |
|
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
24 |
|
Ferrous gluconate |
Approved |
|
|
299-29-6 |
|
Synonyms:
D-gluconic acid, iron(2+) salt (2:1)
Ferric Gluconate
Ferrous gluconate anhydrous
|
Iron(2+) gluconate (1:2)
Iron(II) gluconate, anhydrous
|
|
25 |
|
Iron |
Approved |
|
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
26 |
|
Alfacalcidol |
Approved, Nutraceutical |
|
|
41294-56-8 |
5282181 |
Synonyms:
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1a,3b-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1α,3β-diol
1 alpha-Hydroxycholecalciferol
1 alpha-Hydroxyvitamin D3
1a-Hydroxycholecalciferol
1a-Hydroxyvitamin D3
1a-Hydroxy-vitamin D3
1a-Hydroxyvitamin D3 / 1a-hydroxycholecalciferol
1alpha-Hydroxycholecalciferol
1alpha-Hydroxyvitamin D3
1alpha-Hydroxy-vitamin D3
1alpha-OHD3
1-alpha-Oxycholecalciferol
1-Hydroxycholecalciferol
1-Hydroxycholecalciferol, (1alpha,3alpha-(5Z,7E))-isomer
1-Hydroxycholecalciferol, (1beta)-(5Z)-isomer
1-Hydroxycholecalciferol, (1beta,3beta-(5E,7E))-isomer
1-Hydroxycholecalciferol, aluminum salt
1Α-hydroxycholecalciferol
|
1Α-hydroxyvitamin D3
1Α-hydroxy-vitamin D3
1Α-hydroxyvitamin D3 / 1α-hydroxycholecalciferol
9,10-Secocholesta-5,7,10(19)-triene-1a,3b-diol
9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta-diol
9,10-Secocholesta-5,7,10(19)-triene-1α,3β-diol
Alfacalcidol
Alfacalcidolum
AlfaD
Alphacalcidol
Alsiodol
Bondiol
Doss brand OF alfacalcidol
Eenalfadrie
EinsAlpha
Etalpha
Oksidevit
One-Alpha
Un-alfa
|
|
27 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
|
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
28 |
|
Calcitonin gene-related peptide |
Investigational |
|
|
83652-28-2 |
91976570 |
Synonyms:
2-{[2-({6-amino-2-[(2-{[2-({2-[(2-{[2-({[1-(2-{[2-({2-[(2-{[6-amino-2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[({19-[(2-amino-1-hydroxypropylidene)amino]-16-(carboxymethyl)-6,9,12,15,18-pentahydroxy-7,13-bis(1-hydroxyethyl)-10-methyl-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl}(hydroxy)methylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(1H-imidazol-5-yl)propylidene)amino]-5-carbamimidamido-1-hydroxypentylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-1,3-dihydroxypropylidene}amino)-5-carbamimidamido-1-hydroxypentylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxy-3-methylbutylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxyhexylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene)amino]-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene}amino)-1-hydroxy-3-phenylpropylidene]amino}-3-methylbutanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxyethylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyhexylidene}amino)-1-hydroxypropylidene]amino}-3-phenylpropanoate
Calcitonin gene related peptide
Calcitonin-gene-related peptide
|
|
|
29 |
|
Hydroxycholecalciferols |
|
|
|
|
|
30 |
|
Chelating Agents |
|
|
|
|
|
31 |
|
Calcitonin |
|
|
|
|
|
Synonyms:
4-{[1-({1-[(5-amino-1-{[1-({1-[(1-{[1-(2-{[4-carbamimidamido-1-({2-hydroxy-1-[(1-{[2-hydroxy-1-({[(2-hydroxy-1-{[({3-hydroxy-1-[2-(C-hydroxycarbonimidoyl)pyrrolidin-1-yl]-1-oxobutan-2-yl}-C-hydroxycarbonimidoyl)methyl]-C-hydroxycarbonimidoyl}ethyl)-C-hydroxycarbonimidoyl]methyl}-C-hydroxycarbonimidoyl)propyl]-C-hydroxycarbonimidoyl}-2-(C-hydroxycarbonimidoyl)ethyl)-C-hydroxycarbonimidoyl]propyl}-C-hydroxycarbonimidoyl)butyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-C-hydroxycarbonimidoyl}-2-hydroxypropyl)-C-hydroxycarbonimidoyl]-3-(C-hydroxycarbonimidoyl)propyl}-C-hydroxycarbonimidoyl)-3-methylbutyl]-C-hydroxycarbonimidoyl}pentyl)-C-hydroxycarbonimidoyl]-2-(1H-imidazol-5-yl)ethyl}-C-hydroxycarbonimidoyl)-3-methylbutyl]-C-hydroxycarbonimidoyl}-4-({2-[(2-{[2-({6-amino-2-[(2-{[2-({2-[({22-amino-6,9,12,15,18,21-hexahydroxy-16-[(C-hydroxycarbonimidoyl)methyl]-7-(1-hydroxyethyl)-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosa-5,8,11,14,17,20-hexaen-4-yl}(hydroxy)methylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxyhexylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene}amino)butanoate
Calcihexal
Calcimar
CALCITARE
CALCITONIN
Calcitonin salmon
CALSYNAR
Cibacalcin
Forcaltonin
|
Fortical
Miacalcic
Miacalcin
Recombinant salmon calcitonin
Salcatonin
Salmon calcitonin
Salmon calcitonin (1-32)
Synthetic salmon calcitonin
|
|
32 |
|
Vasodilator Agents |
|
|
|
|
|
33 |
|
Katacalcin |
|
|
|
|
16172926 |
34 |
|
Citrate |
|
|
|
|
|
35 |
|
Neurotransmitter Agents |
|
|
|
|
|
36 |
|
Methacholine Chloride |
|
|
|
|
|
Synonyms:
|
37 |
|
Respiratory System Agents |
|
|
|
|
|
38 |
|
Muscarinic Agonists |
|
|
|
|
|
39 |
|
Cholinergic Agents |
|
|
|
|
|
40 |
|
Iron Supplement |
|
|
|
|
|
41 |
|
Hematinics |
|
|
|
|
|
42 |
|
Dihydroxycholecalciferols |
|
Early Phase 1 |
|
|
|
43 |
|
Radiopharmaceuticals |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 53)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
12-months of Treatment With Burosumab in Children and Adolescents With X-linked Hypophosphatemia: a Prospective Longitudinal Cohort Study |
Unknown status |
NCT04419363 |
Phase 4 |
Burosumab Injection |
2 |
Examining the Effect of Burosumab on Muscle Function Using MR Spectroscopy |
Completed |
NCT04146935 |
Phase 4 |
Burosumab Injection [Crysvita] |
3 |
Comparing the Effectiveness of High or Low Dose of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia |
Recruiting |
NCT03820518 |
Phase 4 |
Calcitriol |
4 |
An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia (XLH) |
Recruiting |
NCT04842032 |
Phase 4 |
KRN23 |
5 |
An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia |
Recruiting |
NCT04842019 |
Phase 4 |
KRN23 |
6 |
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH) |
Completed |
NCT03920072 |
Phase 3 |
Burosumab |
7 |
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02537431 |
Phase 3 |
|
8 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02526160 |
Phase 3 |
|
9 |
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH) |
Completed |
NCT02915705 |
Phase 3 |
Oral Phosphate Supplement;active vitamin D |
10 |
A Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia and a Postmarketing Study of KRN23 Switched From the Phase 3 Trial |
Completed |
NCT03233126 |
Phase 3 |
KRN23 |
11 |
The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH) |
Completed |
NCT00417612 |
Phase 3 |
Paricalcitol |
12 |
A Phase 3 Long-term Extension Study of KRN23 in Patients With X-linked Hypophosphatemic Rickets/Osteomalacia and a Post-marketing Study of KRN23 Switched From the Phase 3 Long-term Extension Study |
Completed |
NCT04308096 |
Phase 3 |
KRN23 |
13 |
An Open Label Trial to Assess the Safety and Efficacy of Burosumab (KRN23), an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome(ENS) and Associated Hypophosphatemic Rickets |
Completed |
NCT03581591 |
Phase 3 |
|
14 |
Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets |
Completed |
NCT01237288 |
Phase 3 |
Z-521 |
15 |
An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGER |
Active, not recruiting |
NCT04695860 |
Phase 3 |
Burosumab |
16 |
Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia: a Multicentre Randomized Controlled Trial |
Not yet recruiting |
NCT04872907 |
Phase 3 |
flowable composite |
17 |
An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02750618 |
Phase 2 |
|
18 |
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) |
Completed |
NCT02312687 |
Phase 2 |
|
19 |
A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02163577 |
Phase 2 |
|
20 |
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia |
Completed |
NCT01340482 |
Phase 1, Phase 2 |
KRN23 |
21 |
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia |
Completed |
NCT01571596 |
Phase 1, Phase 2 |
KRN23 |
22 |
Proposition Pour un Traitement Par Hormone de Croissance Des Enfants Atteints de Rachitisme Hypophosphatemique Familial |
Completed |
NCT02720770 |
Phase 1, Phase 2 |
norditropine simplex |
23 |
A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults With ENPP1 Deficiency |
Recruiting |
NCT04686175 |
Phase 1, Phase 2 |
INZ-701 |
24 |
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH) |
Active, not recruiting |
NCT04188964 |
Phase 1, Phase 2 |
Burosumab |
25 |
Effects of Growth Hormone Treatment on Body Proportions and Final Height Among Small Children With X-Linked Hypophosphatemic Rickets |
Unknown status |
NCT00473187 |
Phase 1 |
somatropin |
26 |
Effect of Calcimimetic (Cinacalcet) on Phosphate-Induced Hyperparathyroidism in Children With Hypophosphatemic Rickets |
Completed |
NCT00195936 |
Phase 1 |
Cinacalcet |
27 |
A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia |
Completed |
NCT00830674 |
Phase 1 |
Placebo;KRN23 |
28 |
A Phase 1, Multicenter, Open-label, Sequential Dose-escalation, Single-dose Study to Assess the Safety and Tolerability of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia. |
Completed |
NCT02181764 |
Phase 1 |
KRN23 |
29 |
Retrospective and Prospective Disease Progression and Quality of Life in X-linked Hypophosphatemia (XLH) |
Unknown status |
NCT04049877 |
|
|
30 |
The Natural History of Generalized Arterial Calcification of Infancy (GACI) With or Without Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) or Pseudoxanthoma Elasticum (PXE) |
Unknown status |
NCT03758534 |
|
|
31 |
Hypophosphatemic Rickets in Norway |
Unknown status |
NCT01057186 |
|
Sevelamer |
32 |
Calcitonin for Treating X-linked Hypophosphatemia |
Completed |
NCT01652573 |
|
nasal salmon calcitonin;Saline Nasal Spray Placebo |
33 |
X-linked Hypophosphatemia and Carbohydrate and Lipid Metabolism: a Role for FGF21? |
Completed |
NCT03596554 |
|
|
34 |
Interplay of FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP) |
Completed |
NCT03489993 |
|
|
35 |
Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency Through the Eyes of Patients and Parents; Burden of Illness Perspectives From Patients and Parents Who Speak English, French or German |
Completed |
NCT04372446 |
|
|
36 |
Milk Products in the Treatment of Hypophosphatemic Rickets: A Randomised Crossover Trial |
Completed |
NCT03348644 |
|
|
37 |
Effect of Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts From Patients With Hypophosphatemic Rickets (HR) |
Completed |
NCT04184661 |
|
|
38 |
Assessment Of Vitamin D Role In The Pathogenesis Of Asthma In Vitamin D Resistent Patients |
Completed |
NCT01578824 |
|
|
39 |
A Natural History Study of Patients With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) |
Completed |
NCT03478839 |
|
|
40 |
Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot |
Completed |
NCT02233322 |
|
|
41 |
Calcitriol Monotherapy for X-Linked Hypophosphatemia: Effects on Mineral Ions, Growth and Skeletal Parameters |
Recruiting |
NCT03748966 |
Early Phase 1 |
Calcitriol |
42 |
Characterising Pain, Quality of Life, Body Composition, Arterial Stiffness, Muscle Function, Bone Density and Geometry in Adult Persons With Hereditary Hypophosphatemia and Healthy Controls |
Recruiting |
NCT04273490 |
|
|
43 |
An International, Multicenter, Prospective, Longitudinal Observational Study for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia |
Recruiting |
NCT03745521 |
|
|
44 |
Dental Implants in Patients With X-linked Hypophosphatemia |
Recruiting |
NCT03879915 |
|
|
45 |
An Observational, Prospective, European, Multicentre, Mixed Methods Study to Describe the Lived Experience of X-Linked Hypophosphatemia (XLH) for Adolescents at End of Skeletal Growth |
Recruiting |
NCT05181839 |
|
Burosumab |
46 |
An International, Multicentre, Prospective, Non-interventional Observational Registry for Patients With X-Linked Hypophosphatemia (XLH) |
Recruiting |
NCT03193476 |
|
|
47 |
Identification of Longitudinal Burden of Disease and Functional Impairment in X-Linked Hypophosphatemia |
Recruiting |
NCT04946409 |
|
|
48 |
A UK Multicentre, Non-interventional, Observational, Health-Related Quality of Life Study for Children and Adolescents With X-linked Hypophosphataemia |
Recruiting |
NCT04819490 |
|
|
49 |
X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP) |
Active, not recruiting |
NCT03651505 |
|
|
50 |
Expanded Access to Burosumab |
Available |
NCT03775187 |
|
|
|